adapalene · Galderma Labs Lp · NDA 020338, 020380, 020748, 021753, 022502
Differin
Earliest generic entry, as listed · earliest of 3 marketed strengths
Open now
No unexpired patents or exclusivities are listed for this product.
Listed patents · 1 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 7998467 | product, use U-1078 | 31 May 2028 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
- 25 Oct 2026Generic approved · 021753-00130 Jun 2026
Products covered · 5
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 020338 · 001 · RLD · discontinued | solution, topical | 0.1% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | open |
| 020380 · 002 · RLD | gel, topical | 0.1% | open |
| 020748 · 001 · RLD | cream, topical | 0.1% | open |
| 021753 · 001 · RLD | gel, topical | 0.3% | open |
| 022502 · 001 · RLD · discontinued | lotion, topical | 0.1% | 31 May 2028 |
Expired or delisted (2)
- US 8435502 · product, use U-1078 · 15 Sep 2026
- US 8709392 · product, use U-1078 · 15 Sep 2026